This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Feb 22;327(8):723-725.

doi: 10.1001/jama.2021.21313.

Sublingual Dexmedetomidine as a Potential New Treatment for Agitation

Affiliations

PMID: 35191943
DOI: 10.1001/jama.2021.21313

Editorial

Sublingual Dexmedetomidine as a Potential New Treatment for Agitation

John K Hsiao. JAMA. 2022.

. 2022 Feb 22;327(8):723-725.

doi: 10.1001/jama.2021.21313.

Author

Affiliation

¹ National Institutes of Health, Bethesda, Maryland.

PMID: 35191943
DOI: 10.1001/jama.2021.21313

No abstract available

PubMed Disclaimer

Comment on

Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
Preskorn SH, Zeller S, Citrome L, Finman J, Goldberg JF, Fava M, Kakar R, De Vivo M, Yocca FD, Risinger R. Preskorn SH, et al. JAMA. 2022 Feb 22;327(8):727-736. doi: 10.1001/jama.2022.0799. JAMA. 2022. PMID: 35191924 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database